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ABSTRACT Actinic keratoses have variants that differ clinically and pathologi-
cally. Proliferative actinic keratoses (PAK) are known to be resistant against 
standard therapies and to create a tendency for the development of invasive 
squamous cell carcinoma (SCC). This study retrospectively reviewed the medi-
cal records of 50 patients with 51 PAK lesions. Fifty patients (40 male, 10 fe-
male) with a mean age of 68.5 were included in the study. Thirty-two (63%) 
PAK lesions were clinically selected for total excision but only 27 of them could 
be totally excised. Among the excised lesions, 13 were reported to be PAK, 13 
were SCC, and 1 was keratoacanthoma. There was no significant difference be-
tween the PAK and SCC groups. Overall, the groups with excised and unexcised 
lesions were statistically similar with respect to age, sex, lesion duration, local-
ization, size, and surface features, but induration was more common in the SCC 
group. The mean follow-up time was 19.7 and 17.0 months in the PAK and SCC 
group, respectively. In conclusion, 25% (13/51) of lesions diagnosed as PAK 
were invasive SCC, which is of clinical and histopathological significance. Our 
results suggest that the definition of PAK should be histopathologically revised 
and that total excisional biopsy instead of punch biopsy should be considered, 
especially for lesions with a proliferative appearance.
KEY WORDS: actinic keratosis, proliferative actinic keratosis, squamous cell 
carcinoma
INTRODUCTION
Actinic keratoses (AK) are keratinocyte-associ-
ated premalignant lesions found in light-skinned 
people due to chronic solar injury (1). Clinically, they 
are characterized as reddish-brown patches, plaques, 
or tumors whose surface may have a rough appear-
ance (1). The annual progression rate of an AK lesion 
to invasive squamous cell carcinoma (SCC) was re-
ported to be 0.025% to 16% (2). However, some au-
thors have advocated that AK is an early-stage SCC le-
sion or a true SCC lesion (3,4). Actinic keratoses have 
been clinically and histopathologically categorized 
as hypertrophic, atrophic, bowenoid, acantholytic, 
pigmented, lichenoid, and proliferative variants (5,6). 
Proliferative actinic keratosis (PAK) was first defined 
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by Goldberg et al. in 1994, and was implicated for SCC 
development due to the spread of anaplastic cells to 
hair follicles and sweat glands and its resistance to 
standard treatments (7,8). In our clinic, we observed 
that histopathological examination of excision ma-
terials found SCC in some of our patients who were 
diagnosed with PAK with the punch biopsy method 
and who subsequently underwent excision for clini-
cal high suspicion of an invasive tumor. Therefore, 
patients diagnosed with PAK were systematically and 
retrospectively assessed on their sociodemographic, 
clinical, histopathological, treatment, and follow-up 
features. 
METHODS
We retrospectively reviewed the digital records, 
photographs, and medical records of 50 patients with 
51 lesions diagnosed as PAK with the punch biopsy 
method at Health Sciences University (HSU) Istanbul 
Training and Research Hospital, Dermatology Outpa-
tient Clinic between January 2010 and October 2016. 
The study was approved by the Local Ethics Commit-
tee of the Health Sciences University (HSU) Istanbul 
Training and Research Hospital. The missing informa-
tion was acquired through telephone interviews with 
the patients.
1. Sociodemographic, clinical, and histopatho-
logical features: Age, sex, time from symptom onset 
to diagnosis (months), follow-up duration (months), 
lesion localization, size (mm), surface features such 
as ulceration, induration, inflammation, and crusts, 
punch biopsy results, and excisional biopsy results if 
available were recorded.
2. Treatment and follow-up features: Treatment 
modalities (conservative follow-up, surgical treat-
ment, cryosurgery), treatment response (complete 
response, partial response), persistence of treatment 
response (stable complete response, recurrence) 
were recorded.
RESULTS
Sociodemographic, clinical, and histopathological 
features: Fifty patients with 51 lesions were included 
in the study. Forty (80%) patients were male and 10 
(20%) were female, with a mean age of 68.5±14.3 
(mean ± Standard Deviation) years. The number and 
percentage distributions of the sociodemographic, 
clinical, histopathological features of the enrolled pa-
tients are presented in Table 1. 
Treatment and follow-up features: As shown in 
Figure 1, thirty-two (63%) lesions were clinically se-
lected for excision, but only 27 of them could be to-
tally excised. Five patients refused excision despite 
our recommendation or their results could not be 
accessed. The histopathological examination of the 
totally excised lesions that were histopathologically 
diagnosed as PAK after punch biopsy revealed that 13 
(25.5%) of these were PAK, 13 (25.5%) were SCC, and 
1 (2.0%) was keratoacanthoma. All SCC lesions were 
invasive and well-differentiated, with none showing 
systemic or lymph node metastasis or neurovascular 
invasion. 
A total of 19 PAK lesions were not excised; 17 of 
them were treated with cryosurgery and 2 lesions 
were conservatively managed. The mean duration 
of follow-up was 17.1±16.3 months. Fifteen of the 
seventeen lesions treated with cryosurgery showed 
complete response and no recurrence. One lesion 
developed recurrence after complete response, while 
one lesion achieved partial response.  
The comparison of the PAK and SCC groups sepa-
rately is shown in Table 2. Seven lesions were exclud-
ed because one lesion was identified as keratoacan-
thoma and follow-up information of 5 patients with 
6 lesions were missing. Thirty patients in total from 
the PAK group and 14 patients from the SCC groups 
were analyzed.
The PAK and SCC groups did not significantly dif-
fer with respect to age, sex, lesion duration, localiza-
tion, size, and surface features (P>0.05). Although no 
significant difference existed among surface features, 
induration was more common in the SCC group than 
the PAK group (78.5% vs 53.3%). The PAK group had 
a mean follow-up duration of 19.7±18.7 months, 
whereas the SCC group was followed for a mean of 
17.0±13.6 months (P>0.05) (Table 2). Some clinical 
images of patients with PAK and SCC at various dif-
ferent localizations are shown in Figure 2 and Figure 
3 (a-d).
The group with lesions that were clinically se-
lected for excision was compared against the group 
whose lesions were not excised (Table 3). Overall 
the excision and follow-up group were also statisti-
cally similar with regard to age, sex, lesion duration, 
localization, size, and surface features. The indura-
tion, ulceration, and inflammation were common 
in the excision group compared with the follow-
up group, but the difference was not significant 
(P>0.05). 
DISCUSSION
AK is the most common epithelial precancerous 
disease that shows predilection for the face, ear, scalp, 
dorsum of hand, and forearms due to chronic ultra-
violet (UV) exposure (9). Clinically and pathologically 
it may appear as hypertrophic, atrophic, bowenoid, 
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acantholytic, pigmented, lichenoid, and proliferative 
variants (5,6). Occupational UV exposure, male sex, 
immunosuppression, and a UV-sensitive skin type are 
the risk factors for AK development (10). 
In our clinic, we observed that some of our patients 
who were diagnosed with PAK with the punch biopsy 
method and who subsequently underwent excision 
for clinical high suspicion of an invasive tumor were 
found to have SCC by histopathological examination 
of excision materials. We conducted this retrospec-
Table 1. Sociodemographic, clinical, and histopathological features of the study population






Age (year) 68.5 ± 14.3 (min: 9 – max: 92)
Disease duration (months) 32.1 ± 11.8
Disease follow-up duration (months) 17.1 ± 16.3 (min: 1 – max: 156)






































*SD: Standard Deviation, AK: Actinic keratosis
Figure 1. Flow diagram of patient treatment. (*SCC: Squa-
mous cell carcinoma, PAK: Proliferative actinic keratosis).
Figure 2. Clinical images of patients with proliferative ac-
tinic keratosis (PAK) at various different localizations (a-d). 
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tive study to assess the relationship between PAK and 
SCC. Invasive SCC was detected in 13 (25.5%) patients 
among 51 lesions initially diagnosed as PAK.   
In 1994, Goldberg et al. showed the spread of dys-
plastic keratinocytes to cutaneous adnexa and de-
fined the proliferative variant of AK in histopathologi-
cal examination of 4 patients with treatment resistant 
AK (7). In that study it was reported that PAK can be 
clinically differentiated from classical AK by its lesion 
width and growth and that classical AKs are frequent-
ly smaller than 1 cm (7). Our study revealed a mean 
lesion size of 11.8±10.9 mm.
AKs are classified as AK I when atypical keratino-
cytes invade the upper 1/3 epidermis, as AK II when 
they invade the upper 2/3, and AK III when they in-
vade the full thickness of the epidermis (11). Even 
though it is classically assumed that full-thickness 
epidermal transformation is required for SCC devel-
opment, AK I has been observed to be the most com-
mon precursor, unlike the classical pathway (12). It was 
Table 2. Comparison of the sociodemographic, clinical, and histopathological features of the squamous 
cell carcinoma (SCC) and proliferative actinic keratosis (PAK) groups separately
PAK
N (%) or mean ± SD*
SCC
N (%) or mean ± SD
P


















































































Table 3. Comparison of the clinical features of the group with lesions that were clinically selected for exci-
sion and the group with lesions not selected for excision
Excision (+)
(N: 27)
N (%) or median
Excision (-)
(N: 24)
N (%) or median
P
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suggested that the adnexal involvement of atypical 
keratinocytes is more common for AK I lesions, which 
is implicated for development of invasive malignant 
lesions in PAKs (12). 
One study reported a risk of invasive malignancy 
of 50% among hyperkeratotic type AKs and noted that 
clinical appearance is a significant factor for malig-
nancy development from AK lesions (13). Quaedvlieg 
et al. reported that AKs greater than 1 cm in size and 
erythema, induration, ulceration, inflammation, rapid 
growth, and bleeding were markers of the develop-
ment of invasive SCC (14). The AK treatment guide-
lines published in 2015 state that biopsy sampling 
should be considered for excluding the possibility of 
invasive malignancy development for lesions show-
ing infiltration, induration, ulceration, pigmentation, 
rapid growth, and pain (15). In contrast to these re-
ports, we did not detect any significant differences 
between the total excision and follow up groups with 
regard to age, sex, lesion duration, localization, size, 
and surface features such as ulceration, induration, 
inflammation, and crusts. We also did not observe 
any significant difference in terms of the same pa-
rameters when the PAK and SCC groups were sepa-
rately analyzed due to a potential margin of error. 
This suggests that the need for excisional biopsy for 
a definitive diagnosis cannot be clinically predicted. 
However, more common, albeit statistically non-sig-
nificant, development of induration in the SCC group 
compared with the PAK group (78.5% vs. 53.3%) sug-
gests that the excision of indurated lesions may be 
considered for excluding SCC.
Although literature reports suggest that AK is fre-
quently an epithelial precancerous disease, some re-
search has labeled it as an early stage of SCC or true 
SCC (5,6). Stockfleth et al. advocated that all AK lesions 
should be assumed to be SCC since it is unknown 
which lesions will progress into SCC (16). In our study, 
the time from PAK diagnosis by punch biopsy to SCC 
diagnosis made by excisional biopsy was less than 1 
month. This suggests that SCC lesions in our study 
did not develop from PAK lesions but were already 
SCC. As the proliferative appearance of actinic kerato-
ses may show a malignant proliferation behavior, we 
are of the opinion that the definition of PAK should be 
histopathologically revised. 
The limitation of our study was the lack of a sec-
ond independent dermatopathologist to examine 
the pathology preparations diagnosed with punch 
biopsy.
While lesion-focused treatments alone can be 
applied for AK treatment, recent studies have indi-
cated that field treatment actually reduces recur-
rences via subclinical UV injury (2). The treatment 
options include cryosurgery, curettage, imiquimod, 
ingenol mebutate, 5-fluoruracil (FU), photodynamic 
treatment, and laser (17). Cryosurgery is an easy-to-
access treatment option that is mostly preferred for 
isolated lesions. Since it is a lesion-focused therapy, 
recurrence rates after treatment have been reported 
as high as 95% (18). In our study, at a mean follow-up 
time of 19.7±18.7 months 15 (88.2%) of 17 patients 
treated with cryosurgery had a complete treatment 
response, whereas 1 (5.9%) patient developed recur-
rence after complete response.
CONCLUSIONS
It is of clinical and histopathological importance 
that invasive SCC was detected in 25.5% of lesions 
diagnosed as PAK. The fact that there was no statisti-
cal difference between the clinical features of the PAK 
and SCC groups as well as the excision and follow up 
groups suggests that the need for excisional biopsy 
for a definitive diagnosis cannot be clinically pre-
dicted. A greater prevalence of induration in the SCC 
group suggests that excision should be considered 
in order to exclude the SCC diagnosis for indurated 
lesions. Our results suggest that the definition of pro-
liferative actinic keratosis should be histopathologi-
cally revised and that total excisional biopsy instead 
of punch biopsy should be considered, especially for 
lesions with a proliferative appearance.
References:
1. Filosa A, Filosa G. Actinic keratosis and squamous 
cell carcinoma: clinical and pathological features. 
G Ital Dermatol Venereol. 2015;150:379-84.
2. Stockfleth E. The importance of treating the field 
in actinic keratosis. J Eur Acad Dermatol Venereol. 
2017;31 (Suppl 2):8-11.
Figure 3. Clinical images of patients with squamous cell 
carcinoma (SCC) at various different localizations (a-d).
Gore Karaali et al. Acta Dermatovenerol Croat
Proliferative actinic keratosis  2019;27(2):75-80
80 ACTA DERMATOVENEROLOGICA CROATICA
3. Brasanac D, Boricic I, Todorovic V, Tomanovic N, 
Radojevic S. Cyclin A and beta-catenin expression 
in actinic keratosis, Bowen’s disease and invasive 
squamous cell carcinoma of the skin. Br J Der-
matol. 2005;153:1166-75.
4. Lober BA, Lober CW, Accola J. Actinic keratosis is 
squamous cell carcinoma. J Am Acad Dermatol. 
2000;43:881-2.
5. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, 
Eberle J, Kerl H, et al. Actinic keratosis is an early 
in situ squamous cell carcinoma: a proposal for re-
classification. Br J Dermatol. 2007;156 (Suppl 3):8-
12.
6. Frost CA, Green AC. Epidemiology of solar kerato-
ses. Br J Dermatol. 1994;131:455-64.
7. Goldberg LH, Joseph AK, Tschen JA. Proliferative 
actinic keratosis. Int J Dermatol. 1994;33:341-5.
8. Goldberg LH, Chang JR, Baer SC, Schmidt JD. Pro-
liferative actinic keratosis: three representative 
cases. Dermatol Surg. 2000;26:65-9.
9. James WD, Berger T, Elston D, eds. Epidermal Nevi, 
Neoplasms, and Cysts. In: Andrews’ Diseases of 
the Skin Clinical Dermatology. 11th ed. Saunders 
Elsevier; 2011. pp 629-630.
10. Hensen P, Müller ML, Haschemi R, Ständer H, Lu-
ger TA, Sunderkötter C, et al. Predisposing factors 
of actinic keratosis in a North-West German popu-
lation. Eur J Dermatol. 2009;19:345-54.
11. Fernandez Figueras MT. From actinic keratosis to 
squamous cell carcinoma: pathophysiology revisi-
ted. J Eur Acad Dermatol Venereol. 2017;31 (Suppl 
2):5-7.
12. Fernández-Figueras MT, Carrato C, Sáenz X, Puig 
L, Musulen E, Ferrándiz C, et al. Actinic keratosis 
with atypical basal cells (AK I) is the most common 
lesion associated with invasive squamous cell car-
cinoma of the skin. J Eur Acad Dermatol Venereol. 
2015;29:991-7.
13. Suchniak JM, Baer S, Goldberg LH. High rate of 
malignant transformation in hyperkeratotic ac-
tinic keratoses. J Am Acad Dermatol. 1997;37:392-
4.
14. Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Ac-
tinic keratosis: how to differentiate the good from 
the bad ones? Eur J Dermatol. 2006;16:335-9.
15. Werner RN, Stockfleth E, Connolly SM, Correia O, 
Erdmann R, Foley P, et al. Evidence- and consen-
sus-based (S3) Guidelines for the Treatment of 
Actinic Keratosis – International League of Der-
matological Societies in cooperation with the Eu-
ropean Dermatology Forum – short version. J Eur 
Acad Dermatol Venereol. 2015;29:2069-79.
16. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Peham-
berger H, Kerl H. European Skin Academy. Deve-
lopment of a treatment algorithm for actinic ke-
ratoses: a European Consensus. Eur J Dermatol. 
2008;18:651-9. 
17. Dirschka T, Gupta G, Micali G, Stockfleth E, Bas-
set-Séguin N, Del Marmol V, et al. Real-world ap-
proach to actinic keratosis management: practical 
treatment algorithm for office-based dermatolo-
gy. J Dermatolog Treat. 2016;13:1-12.
18. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann 
I, Sterry W, Stockfleth E. A randomised study of 
topical 5% imiquimod vs. topical 5-fluorouracil vs. 
cryosurgery in immunocompetent patients with 
actinic keratoses: a comparison of clinical and his-
tological outcomes including 1-year follow-up. Br 
J Dermatol. 2007;157(Suppl 2):34-40.
Gore Karaali et al. Acta Dermatovenerol Croat
Proliferative actinic keratosis  2019;27(2):75-80
